Rosetta Biosoftware Licenses the Rosetta Resolver® Gene Expression Analysis System to FoxHollow Technologies

SEATTLE, Wash., and REDWOOD CITY, Calif., March 13, 2006 – Rosetta Biosoftware announced today that FoxHollow Technologies has licensed the Rosetta Resolver system for research on cardiovascular disease. FoxHollow Technologies developed and markets the SilverHawk™ Plaque Excision System, an atherosclerotic plaque excision device approved in the U.S. for the treatment of peripheral arterial disease (PAD).

Source: Rosetta Biosoftware